Results 21 to 30 of about 169,585 (295)

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

Journal of Market Access & Health Policy, 2017
Background: Adverse event (AE) reporting in clinical trials does not fully capture the patient-level perspective and comparing tolerability across treatments or among studies is difficult.
Clément François, Alice Guiraud-Diawara, Christophe Lançon, Pierre Michel Llorca, Ann Hartry, Lene Hammer-Helmich, Djamel A. Zighed, Adrian Tanasescu, Mondher Toumi   +8 more
doaj   +1 more source

Treatment of early onset schizophrenia: Recent trends, challenges and future considerations

Frontiers in Psychiatry, 2012
Early onset schizophrenia (onset before adulthood) is a rare, severe and chronic form of schizophrenia. Antipsychotic treatment remains the mainstay of treatment although current medications provide suboptimal response at best.
Nora S Vyas, Nitin eGogtay
doaj   +1 more source

Quetiapine-induced bicytopenia. Case report and literature review

European Psychiatry, 2021
Introduction Low white blood cell counts and agranulocytosis are a relatively rare side effect of atypical antipsychotic treatment. Like most atypical antipsychotics, quetiapine only has a 1%-4% risk of low blood cell count.
T. Gutiérrez Higueras, S. Vicent Forés, S. Sainz De La Cuesta Alonso, F. Calera Cortés   +3 more
doaj   +1 more source

Recovery from psychosis : physical health, antipsychotic medication and the daily dilemmas for mental health nurses [PDF]

, 2015
This paper considers some of the dilemmas experienced by Mental Health Nurses everyday when faced with the seemingly conflicting relationships that exist between recovery, antipsychotics and the physical health of people experiencing psychosis.
Bressington, D., Bressington, Daniel, White, J., White, Jacquie   +3 more
core   +1 more source

A randomized-controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia

Frontiers in Pharmacology, 2013
Objective: Medication adherence is extremely important in preventing relapse and lowering symptoms in schizophrenic patients. However, estimates show that nearly half of these patients have poor adherence. The Brief Adherence Rating Scale (BARS) seems to
Emmanuel eStip, Emmanuel eStip, Emmanuel eStip, Philippe D. Vincent, Philippe D. Vincent, Philippe D. Vincent, Catherine eGuevremont, Simon eZhornitsky, Constantin eTranulis, Constantin eTranulis, Constantin eTranulis, Juliette eSablier, Juliette eSablier   +12 more
doaj   +1 more source

Minimal-medication approaches to treating schizophrenia [PDF]

, 2009
UK guidelines for treating people diagnosed with schizo phrenia currently emphasise the primacy of antipsychotic medication, with or without psycho-socially based interventions as circumstances dictate.
Aderhold, Agar-Jacomb, Barnes, Bennett, Burston, Calton, Carpenter, Ciompi, Ciompi, Cooper, Davis, Day, Descartes, Digby, Fins, Fulford, Gray, Griesinger, Grisso, Harrow, Helen Spandler, Hogarty, Hyman, Loebel, Mosher, Mosher, Mosher, Pasamanick, Pincus, Podvoll, Porter, Pullen, Rappaport, Rose, Seikkula, Seikkula, Statsny, Tim Calton, Warner, Watkins, Wirt   +40 more
core   +1 more source

Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia

Neuropsychopharmacology Reports, 2020
Aim It is well accepted that early improvement with antipsychotics predicts subsequent response in patients with schizophrenia. However, no study has examined the contribution of individual symptoms rather than overall symptom severity as the predictors.
Kamiyu Ogyu, Yoshihiro Noda, Kazunari Yoshida, Shin Kurose, Fumi Masuda, Yu Mimura, Hana Nishida, Eric Plitman, Ryosuke Tarumi, Sakiko Tsugawa, Masataka Wada, Takahiro Miyazaki, Hiroyuki Uchida, Ariel Graff‐Guerrero, Masaru Mimura, Shinichiro Nakajima   +15 more
doaj   +1 more source

Pdxdc1 modulates prepulse inhibition of acoustic startle in the mouse. [PDF]

, 2017
Current antipsychotic medications used to treat schizophrenia all target the dopamine D2 receptor. Although these drugs have serious side effects and limited efficacy, no novel molecular targets for schizophrenia treatment have been successfully ...
Boutros, PC, Feldcamp, LA, Fletcher, PJ, Nobrega, JN, Raymond, R, Wong, AHC   +5 more
core   +1 more source

Patterns of management of patients with dual disorder (psychosis) in Italy: a survey of psychiatrists and other physicians focusing on clinical practice [PDF]

, 2018
© 2018 Clerici, de Bartolomeis, De Filippis, Ducci, Maremmani, Martinotti and Schifano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).Patients with severe psychotic disorders such as ...
Acquas, Akiskal, Archie, Bacopoulos, Blum, Blum, Bowirrat, Carra, Connelly, Cuomo, De Bartolomeis, De Bartolomeis, Degenhardt, Delisi, Fantini, Fiorillo, Getzen, Gouzoulis-Mayfrank, Grob, Hertzog, Howes, Iasevoli, Kerner, Lambert, Maremmani, Martin, Martinotti, Nesvag, Ostuzzi, Papageorgiou, Regier, Roncero, Rovai, Rubino, Samaha, Samalin, Sugawara, Szkultecka-Debek, Ventriglio, Volkow   +39 more
core   +4 more sources

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting

Frontiers in Psychiatry, 2023
Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were ...
Lluis Niell Galmes, Elmars Rancans
doaj   +1 more source